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Fluorescence polarization assay (FPA), a serological assay, was validated as an alternative 
test for the rapid and cost-effective diagnosis of bovine brucellosis, with the aim of 
improving the control of brucellosis in South Africa. The FPA is anticipated to distinguish 
between vaccinated and infected cattle, circumventing the challenge associated with the 
tests that are currently used.  Positive cattle serum samples (n =420) confirmed by 
Complement Fixation Test were tested in conjunction with serum samples (n = 446) from 
non-infected cattle initially tested on Rose Bengal Test, CFT and compared with FPA. The 
optimum cut-off value that offers the highest diagnostic sensitivity (Dsn) and diagnostic 
specificity (Dsp) was determined as 87 mP with the use of ROC analysis. The Dsn and Dsp 
of FPA using this cut-off value was calculated at 99.09% - 100% and 68.09%- 76.61% 
respectively with a 95% confidence interval (cl). The area under curve (AUC) was calculated 
at 0.9842 with a 95% standard error (S.E) of 0.005532 with positive and negative likelihood 
ratio (+LR) (-LR) at 3.643 and 1.002, respectively. The FPA was found to be as effective 
as CFT and should be considered because of its accuracy and other advantages such as 
speed, high throughput and the objectivity of the interpretation of results that can be 
obtained electronically by the (PHERAstar) machine. The test should be included in routine 
serological diagnosis for brucellosis. 









I- Fluorescence polarization assay (i-FPA) ukuhlolwa kwe-serological okuqinisekiswe 
njengenye indlela yokuhlola ukuxilongwa okusheshayo nengabizi kwe-bovine brucellosis, 
okuzokwenza ngcono ukulawulwa kwe-brucellosis eNingizimu Afrika. Ngaphezu 
kwalokho, i-FPA kulindeleke ukuthi yehlukanise phakathi kwezinkomo ezigonyiwe 
nezithelelekile futhi lokhu kuzonciphisa inselelo ehambisana nokuhlolwa esetshenziswa 
njengamanje. Amasampula amahle avumayo we-serum ezinkomo (n 
= 420) aqinisekiswa yi-CFT ahlolwe ngokuhlangana namasampula e-serum (n = 446) 
avela ezinkomeni ezingathelelekile ezahlolwa kuqala ku-RBT, CFT futhi kuqhathaniswa 
ne-FPA. Inani elinqunyiwe elikhulu elinikezela ukuzwela okuphezulu kokuxilonga (i-Dsn) 
kanye nokucaciswa kokuxilongwa (i-Dsp) kunqunywe njenge-87 mP kusetshenziswa 
ukuhlaziywa kwe-ROC. I-Dsn ne-Dsp ye-FPA esebenzisa leli nani elisikiwe libalwe 
ngama-99.09% - 100% no-68.09% - 76.61% ngokulandelana kwesikhathi sokuzethemba 
esingu-95% (cl). Indawo engaphansi kwe-Curve noma ijika thizeni (i-AUC) ibalwe ku-
0.9842 enephutha elingu-95% elijwayelekile (SE) lika- 0.005532 elinezilinganiso ezinhle 
nezimbi ze-likehood (+ LR) (-LR) ngo-3.643 no- 1.002, ngokulandelana. I-FPA isebenza 
njenge-CFT futhi kufanele ibhekwe ngenxa yokunemba eneqiniso kwayo nezinye izinzuzo 
ezifana nejubane lokuthola imiphumela kanye nenhloso yokuchazwa kwemiphumela 
engatholakala ngomshini wekhomphuyitha (PHERAstar), i-FPA kufanele ifakwe 
ekuhlolweni okuvamile ngokujwayelekile kwe-serological ye-brucellosis. 
 
Amagama abalulekile: i-B. Abortus, i-FPA, izinkomo, ukuqinisekiswa, i-Serology, i- RBT, 
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CHAPTER 1: INTRODUCTION 
 
1.1 Background 
Bovine brucellosis is a zoonotic bacterial disease caused by Brucella abortus, which is a 
gram-negative, non-mobile, non-spore-forming, and rod-shaped bacterium (Mahmood et 
al., 2015). It is a non-capsulated (Jaff, 2016) and slow growing bacterium (Hendaus et al., 
2015) with oxidative metabolic patterns (Gorofolo et al., 2017). It is an intra-cellular (occurs 
inside body cells) organism that can cause an extended and sometimes life-long, chronic 
disease in both human and animal (Preez and Malan, 2015; Chisi et al., 2017). 
Brucella infection spreads rapidly in a cattle herd that is not vaccinated and causes 
abortions in pregnant cows during the late stage of pregnancy. Infected cows will abort once 
but the following pregnancy will be normal. This usually happens in a herd where brucella is 
endemic (Preez and Malan, 2015). Some cattle can withstand infection and a small 
percentage of infected cows recover spontaneously (Preez and Malan, 2015). Brucellosis 
is one of the most important re-emerging zoonotic diseases in many countries, in which 
infected animals are the source of infection (Mohammed, 2015). In South Africa, on 16 
November 2020, the KwaZulu-Natal Agriculture Department confirmed an outbreak of 
brucellosis in the northern part of KwaZulu-Natal. There were more than 400 confirmed 
cases of brucellosis in cattle. During a television interview on eNews Channel Africa 
(eNCA), some farmers in rural areas confirmed a lack of knowledge about the disease and 
requested government intervention. 
Control and prevention of brucellosis depends mainly on rapid and sensitive diagnostic tests 
(Trangadia et al., 2012) that allow the implementation of control measures such as isolation 
and “test and slaughter” policy. The conventional serological tests for the diagnosis of 
Brucellosis are subjected to certain limitations, for instance Rose Bengal Test has lower 
specificity and may result in strongly positive sera testing negative (OIE, 2009). 
Complement Fixation Test cannot distinguish between cattle that are vaccinated with B. 
abortus strain 19 from those exposed to cross-reacting microorganisms from cattle infected 
with B. abortus (Gall et al., 2000).  Many serological tests are available for the diagnosis of 




agglutination test (STAT) and complement fixation test (CFT) have been used extensively 
to diagnose Brucellosis in animals (Trangadia et al., 2012). 
1.1.1 History of Brucellosis 
Brucellosis is diagnosed by isolation and identification of the causative organism. Bruce 
and a co-worker first reported this in 1887 when they isolated Brucella melitensis from the 
spleen of a soldier who died from acute brucellosis. This species is highly pathogenic for 
humans. The disease originated from infected goats (Nielsen, 2002).  A study reported lytic 
lesions of the lumbar vertebrae in "southern Ape of Africa" (Australopithecus africanus) 
suggestive of brucellosis. The suspected source of infection could be the consumption of 
infected tissues from wild animals (Rossetti et al., 2017; D' Anastasios et al., 2009). 
At the beginning of the 20th century, Benhard Bang identified Brucella abortus as the cause 
of abortions in cattle. It had been the main etiologic factor of brucellosis in animals and 
humans, also known as Bang’s disease, and was isolated from aborting cattle for many 
years (Gorofolo et al., 2017). In 1914, Taum described Brucella suis causing disease 
mainly in swine but also in humans (Nielsen, 2002). Brucella canis was isolated from dogs 
and suspected to cause illness in humans. Carmichael who isolated the bacillus from the 
placentas, fetuses, and vaginal discharges of bitches that aborted first described it in 1966. 
The disease was diagnosed in Beagle dogs in United States.  Brucella neotomae was 
isolated from rats in the United States while Brucella ovis infects sheep and goats.  Brucella 
marina and Brucella ceti were found in sea mammals namely whales and seals in the 
Atlantic Ocean. Brucella marina and Brucella pinnipedialis were found in sea mammals. 
Brucella microti was isolated from the common vole (Microtus arvalis) in the Czech 
Republic, from the soil in the sea area and from mandibular lymph nodes of wild red foxes. 
Lastly, Brucella inopinata was isolated from the breast implant wound of a woman with 
clinical signs of brucellosis (Galinska and Zagorski, 2013). 
Each of these Gram-negative bacteria infects a different group of land and aquatic 
mammals, including swine, cattle, goats, sheep, dogs, dolphins, whales, seals, and desert 




1.2 Problem statement 
 
Brucellosis is one of the most neglected zoonotic bacterial diseases that can cause public 
health threats involving domestic animals, wild animals, and humans (Aworh et al., 2017). 
The economic implications of brucellosis in a cattle herd is huge worldwide, affecting mostly 
breeding animals with associated losses in productivity due to abortions, stillbirths, weak 
offspring, extended inter-calving period, unexpected deaths, and reduced milk production. 
The disease also causes major impediments for trade and export of livestock (Tasiame et 
al., 2016). The zoonotic aspect of this disease and the confusing clinical signs effects in 
humans raise a need to continuously control brucellosis (Dorneles et al., 2015). Currently 
used tests such as Rose Bengal Test (RBT), Serum Agglutination Test (SAT) and 
Complement Fixation Test (CFT) have shortcomings due to low sensitivity, false-negatives, 
and non-specific reactions, respectively. 
 
The RBT has some disadvantages of low sensitivity mostly in chronic cases, relatively low 
specificity in endemic areas and prozones making strongly positive sera test negative 
(Geresu and Kassa, 2016). A false-negative reaction arises due to the prozones phenomenon 
(Trangadia et al., 2012). The SAT is unacceptable for international trade due to non-specific 
reactions (Delegates, 2016; OIE, 2004). The CFT has limitations with haemolysed serum 
samples, the anti-complement activity of some sera and the occurrence of the prozones 
phenomena false-negatives resulting from high antibody titre that interferes with the 
formation of the antigen-antibody complex (Geresu and Kassa, 2016).  The CFT is extremely 
challenging, as it requires trained and qualified personnel to perform the test and serial dilutions are required 
for titrations prior testing of samples (OIE, 2004) 
Handling aborted materials or attending to retained placentas or dystocia without protective 
gear is a common practice among most field veterinary assistants, abattoir workers, and in 
many rural pastoral settings. This may suggest that animal health workers and rural 
communities are also at great risk of contracting the disease if the disease is present in 








• The sensitivity and specificity of FPA are not lower than those of RBT and CFT for 
the diagnosis of brucellosis in cattle. 
• The repeatability of FPA will not be more than 2 SD. 
• The reproducibility of FPA will not be more than 2 SD. 
• The Pearson correlation coefficient between FPA and standard tests such as RBT 
and CFT will not be more than 1. 
1.4 Aim and Research objectives 
The study aimed to validate the Fluorescence polarization assay (FPA) as an additional 
test for the rapid and cost cost-effective diagnosis of Brucellosis, which will improve the 
control of Brucellosis in South Africa. 
The specific objectives are: 
• To evaluate the specificity and sensitivity of FPA using cattle field sera. 
• To determine the reproducibility of FPA 
• To determine the repeatability of FPA 
• To evaluate the correlation coefficient between FPA and standard tests such as RBT 
and CFT. 
1.5 Significance and motivation of the study 
Brucellosis is a zoonotic and controlled disease. The validation of FPA will result in 
improved diagnosis of affected cattle in South Africa. Validation is an ongoing activity that 
is crucial to all accredited laboratories. After the study is completed, the Serology laboratory 
will continue with validation especially if the test is approved to be implemented in South 
Africa, to gather more validation data prior to roll out in other laboratories. This test will 
contribute significantly to the improvement and efficiency of the eradication program due 




It will be helpful to laboratories seeking appropriate tests that do not require washing steps, 
longer incubation periods and are not time-consuming. The FPA may be preferred over 
other tests because of its characteristic cut-off adjustment useful in different 
epidemiological situations and its potential application in the field. Besides, the FPA is 
anticipated to differentiate vaccinated from diseased cattle and this will circumvent the 
challenge associated with the tests currently in use. The test can be automated and used 
to improve quality assurance processes, hence making it suitable for eradication programs, 
national serological surveys, and laboratories handling large volumes of brucellosis 
samples, as it is the case in South African laboratories (Kangumba, 2015).  The FPA test 
has been used on stored whole blood samples and on haemolysed samples (Nielsen et 
al., 2001).  It has a higher ability to detect low antibody titers unlike RBT (Muma et al., 
2009).  Adding to the abovementioned advantages, the diagnostic specificity and 
sensitivity of FPA are higher when compared to other tests used in different species 







CHAPTER 2: LITERATURE REVIEW 
 
2.1 Brucellosis in humans 
 
2.1.1 Historical contexts 
 
Human brucellosis was first confirmed in Iraq in 1938. Indeed, in Iraqi Kurdistan, brucellosis 
in humans is a widespread disease that remains a challenging health problem (Jaff, 2016). 
It has been reported in Southeast Asia, particularly Indonesia, Malaysia, Singapore and 
Myanmar, and Thailand. It was recognized as an emerging zoonotic disease in Southeast 
Asia and is frequently caused by Brucella melitensis (Zamri-Saad and Kamarudin, 2016). 
Brucellosis is listed amongst the seven neglected zoonotic diseases by the World Health 
Organization (Ayoola et al., 2017; Aworh et al., 2017; Franc et al., 2018) considering the 
impact it has on both human and animal health (Njeru et al., 2016). Brucellosis is under-
reported, often misdiagnosed even in higher-income countries, and is considered one of 
the main neglected zoonotic diseases (Norman et al., 2016). 
Human brucellosis is endemic to certain regions and has been reported worldwide, with 
more than 500 000 cases reported annually (Mahmood et al., 2015; Aloufi et al., 2016; Jezi 
et al., 2019).  Research evidence shows that brucellosis is more common in countries with 
poor standardized animal and public health programs and interventions (Jaff, 2016).  Major 
endemic areas include countries of the Mediterranean basin, Middle East, Including Iraq 
and Iraqi Kurdistan, the Indian subcontinent, and parts of Mexico and Central and South 
America (Jaff, 2016). 
It is estimated that the number of human brucellosis cases may be up to 26 times higher 
than the 500,000 cases reported annually (Jaff, 2016; Avijgan et al., 2019). The disease 
occurs naturally in the populations of developing areas of the world where numbers are 




that are affected include Ethiopia, Chad, Tanzania, Nigeria, Uganda, Kenya, Zimbabwe, 
and Somalia where brucellosis in humans is related to infection of domestic cattle, camels, 
goats, and sheep (Yang et al., 2017). 
Brucellosis is a common zoonotic infection in the Middle East, South and Central Asia, 
South and Central America, North and East Africa as well as in the Mediterranean countries 
of Europe (Hendaus et al., 2015). Eastern Mediterranean countries have shown an 
incidence of more than 100 cases per 100,000 persons/year, with the highest figures in 
Syria, Lebanon, Iraq, Saudi Arabia, Sudan, and Oman (Garcell et al., 2016). The disease 
continues to progress at high rates in Latin America, South East Asia, the Middle East, and 
the Persian Gulf (Banai et al., 2018). 
Brucellosis is an overlooked infection of widespread geographic distribution associated with 
traveling and importing contaminated goods from endemic areas (Brehin et al., 2016). The 
entire human population is susceptible to contracting human brucellosis and it was stated 
that in prevalent areas, a quarter of the patients are younger than 14 years of age, with a 
rate of childhood infection of 11% to 56% (Bosilkovski et al., 2015). In France, a case of 
brucellosis in a 16-months-old patient hospitalized for an acute febrile illness was 
discovered; the child had eaten a cake made from unpasteurized goat’s milk that was 
imported from Algeria (Brehin et al., 2016). A 27-year-old man from Western Cape, South 
Africa was diagnosed with B. melitensis infection after the laboratory confirmed the isolation 
of Gram-negative bacilli in 2014. After 3 days of incubation, an epidemiological 
investigation led to two other people being diagnosed with brucellosis after eating meat 
from a goat that had recently given birth on a farm (Wojno et al., 2016). 
Shimol reported an outbreak of brucellosis acquired through camel milk affecting 15 
members of an extended family in Israel (Shimol et al., 2012). An outbreak related to the 
consumption of raw cheese was described in Lebanon, as it was a cluster of six cases of 
breast brucellosis in Taif (Saudi Arabia) (Garcell et al., 2016). 
 
2.1.2 Transmission of brucellosis to humans: consumption of contaminated animal 
products 
Brucella spp is excreted in milk and may be present in the offal and meat of infected animals 




(Aworh et al., 2017; Mahmood et al., 2015) and consuming untreated milk products leads 
to approximately a half-million cases of brucellosis in humans around the world every year 
(Bano and Lone, 2015). A number of publications have reported acquired infections through 
the consumption of unpasteurized goat’s milk, camel milk, raw cheese and infected goat 
meat (Brehin et al., 2016; Wojno et al., 2016; Garcell et al., 2016 and Shimol et al., 2012). 
In humans, the disease is often caused by Brucella melitensis, which is the species 
associated with more severe disease (Wojno et al., 2016) as the most pathogenic species, 
followed by Brucella suis, while Brucella abortus is considered the mildest type of 
brucellosis (Galinska and Zagorski, 2013; Norman et al., 2016 and Wojno et al., 2016). 
Brucellosis may develop after a prolonged incubation period of up to several months, and 
manifestations are versatile often making a diagnosis challenging (Norman et al., 2016). 
Since there is no human vaccine, livestock vaccination is an effective method of preventing 
human infections (Jezi et al., 2019) and the eradication of brucellosis is a major public health 
challenge in many countries (Jaff, 2016). 
 
 












2.1.3 Reservoirs of Brucella 
The natural reservoirs of Brucella are domestic animals, primarily cattle, sheep, goats as well 
as wild animals (Galinska and Zagorski, 2013). After penetration into the body, the bacilli 
proliferate in the lymphatic system, mainly in the lymph nodes, and subsequently break 
through the protective barrier to penetrate various organs. (Galinska and Zagorski, 2013). 
Once in the lymphatic system, the bacteria first multiply in the regional lymph nodes and is 
later carried by the lymph and blood to different organs (Bano and Lone, 2015). Brucellae 
quickly translocate across the mucosal epithelium layer in vivo and are endocytosed by 
mucosal macrophages and dendritic cells (de Figueiredo et al., 2015). The type of Brucella 
spp. to which an individual is exposed determines the risk of the disease and its severity. 
This will be influenced by the species of host animal acting as a source of infection (Dr 
Corbel, 2006). 
 
2.1.4 Transmission of brucellosis to humans: via direct contamination 
 
Animal to human transmission is caused by direct contamination with infected animals, 
placenta, and aborted fetuses (Jaff, 2016; Zamri-Saad and Kamarudin, 2016) as well as by 
direct contact with the infected animal through skin abrasions or mucous membrane (Njeru 
et al., 2016). The transmission can also be caused by direct contact with secretions from 
infected animals, inhalation of contaminated animal feces, and infected animal products 
(Alsaif et al., 2018; Ayoola et al., 2017). People working in close contact with infected 
materials like abattoir workers, veterinarians, and laboratory workers are easily infected 
through skin abrasion (Mantur and Amarnath, 2008).  Tuon documented human-to-human 
transmission of brucellosis via blood transfusion, bone marrow transplantation, sex, 
transplacental or perinatal exposure, and breast milk in humans (Tuon et al., 2017). Contact 
with contaminated substances of animal origin as well as inhalation of aerosolized 





2.1.5 Virulence factors of Brucella 
 
The Brucella bacteria has several virulence factors for invasion and many mechanisms for 
evading cellular immunity, which enables them to survive the human immune responses 
and replicate within intracellular niches (Amjadi et al., 2019). Recently a urease enzyme 
was identified as an important determinant of virulence as this enzyme protects Brucella 
bacteria in their passage through the stomach by the oral route, which is the major way of 
infection in human brucellosis (Bano and Lone, 2015). 
 
2.1.6 Symptoms of human Brucellosis 
 
Clinical signs and symptoms of brucellosis are not specific, and the diagnosis mostly relies 
on incorporating clinical, epidemiological, and serologic findings. Serologic tests play a 
fundamental role in the diagnosis of this disease (Avijgan et al., 2019). The most frequent 
symptoms of human brucellosis are fever, chills or shaking rigors, malaise, generalized 
aches, pain all over the body, joint and low back pain, headaches, anorexia, easy tiredness, 
nausea, loss of appetite, and general weakness (Jezi et al., 2019; Khazaei et al., 2016). 
The incubation period of brucellosis normally is 1 to 3 weeks, but it can be several months 
before any sign of infection is detected (Roushan and Ebrahimpour, 2015). Symptoms 
observed can include recurrent fevers, arthritis, swelling of the testicles, enlargement of the 
heart, neurologic symptoms (in up to 5% of all cases), chronic fatigue, depression, and 
hepatomegaly and/or splenomegaly (Jaff, 2016). Nonspecific influenza-like symptoms 
observed in humans include pyrexia, diaphoresis, fatigue, anorexia, myalgia, and arthralgia 
(de Figueiredo et al., 2015). The great variety of clinical shreds of evidence of human 
brucellosis makes the diagnosis relatively difficult. This absence of characteristic symptoms 
makes it challenging to differentiate brucellosis from numerous febrile diseases that 
commonly appear in the same regions making laboratory testing very important for 
diagnosis (Zakaria, 2018). Besides, in the absence of human brucellosis vaccine, the most 
effective strategy to control human brucellosis is to control brucellosis in animal populations. 
In recent decades, the development of an effective vaccine for brucellosis 




  2.1.7 Treatment of human Brucellosis 
 
Treatment of human brucellosis is frequently not successful due to reoccurrence. Double 
or triple treatments with an aminoglycoside (doxycycline- streptomycin/gentamicin or 
doxycycline-rifampicin-streptomycin/gentamicin) suggestively decrease treatment 
letdown and setbacks proportion, as indicated in table 1 and table 2. They are presently 
preferred as first-line treatment procedures. The period of treatment is a minimum of six 
weeks for doxycycline, and rifampicin up to two weeks for aminoglycoside therapy (daily 
intramuscular injections), see Tables 2.1 and 2.2 for details. Patients require prolonged 
follow-up to monitor further complications or relapses (Frean et al., 2018). 
The patients are treated with combination of either two or three antimicrobials.  When used 
in combination, tetracycline, doxycycline, trimethoprim/sulfamethoxazole, and rifampin are 
administered for at least 45 days. Streptomycin is used for the first 14-30 days, and 
gentamicin for the first 7-10days. In patients that manifested neurobrucellosis, myocarditis, 
or therapeutic failure, treatment duration should be 60-180 days (Bosilkovski et al., 2015) 
The treatment course of brucellosis in children is longer and is argued that rare treatment 
failure is high among children. Children older than 8 years are treated with doxycycline for 
45 days to 8 weeks plus gentamicin for 5 days or 7 days respectively or doxycycline for 45 
days and streptomycin for 14 days (Khazaei et al., 2016; Roushan and Ebrahimpour, 2015). 
Treatment of complications such as spondylitis, osteomyelitis, neurobrucellosis and 





Table 2. 1: Treatment regimens for Brucellosis (Frean et al., 2018). 
 













1-2 weeks Intramuscular 
gentamicin 5mg/kg. 
day 












4-6 weeks  
≥8y Doxycycline plus 
rifampicin 
4-6 weeks  
Focal - adults Doxycycline 12 weeks  Oral doxycycline, 
1000-2000mg/day 
Spondylitis Plus, streptomycin 
or gentamicin 
2 weeks Intramuscular 
gentamicin 5mg/kg. 
day 
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Or doxycycline plus 
ciprofloxacin 
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Neurobrucellosis Doxycycline plus 











Surgery if indicated 
6 weeks to 6 
months, depending 




Focal – children     
<8y 
 
Cotrimoxazole 6 weeks at least  
Plus, streptomycin 
or gentamicin 
2 weeks  
≥8y Doxycycline 
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added to either 
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6 weeks at least 
 







(avoid in the last 
week before 
delivery, risk of 
kernicterus.  









second line to 
doxycycline or 
rifampicin; triple 
therapy has better 
cure rates. 
 Oral Cotrimoxazole 







Table 2. 2: Antibiotic dosage for Brucellosis treatment (Frean et al., 2018). 
 
Cotrimoxazole Trimethoprim 10 mg/kg/d 
(max. 480 mg/d), 
sulfamethoxazole 50mg/ 
kg/d (max/ 2g/d) 
In 2 doses/day 
Doxycycline 2-4 mg/kg/d (max 200mg/d) In 2 doses/day 
Rifampicin 15-20 mg/kg/d) max 2g/d) In 1 or 2 doses/day 
Gentamicin 5 mg/kg/d In 1 to 3 doses/day 
Streptomycin 20-40 mg/kg/d (max 1/d) In 2 doses/day 
Ciprofloxacin 1 g/d In 2 doses/day 






2.2 Brucellosis in animals 
2.2.1 Brucellosis in pigs 
 
Brucella suis is a Gram-negative coccobacillus in the family Brucellaceae (class 
Alphaproteobacteria). Brucella suis biovars 1, 2, and 3 are the Brucella species usually found 
in pigs (The center for food science and public health, 2018). Brucellosis in swine is a 
disease caused by infection with intracellular bacteria from the genus Brucella, and a 
disease of economic importance with worldwide distribution (Olsen and Tatum, 2017) and 
has a high economic impact in pig farms (Dieste-Perez et al., 2015). Although the disease is 
associated with reproductive losses in swine worldwide, its primary importance is related to 
its zoonotic capability of causing clinical symptoms in humans (Olsen & Tatum, 2017). 
Brucella suis is common among domesticated pigs in parts of Latin America and Asia. 
Control programs have eliminated or nearly eliminated this organism in some countries 
including several European nations, the U.S., Canada, and Australia. However, B. suis is still 
maintained in feral pigs or wild boar in many of these regions, resulting in sporadic 
transmission to domesticated swine. Infected pigs have occasionally been documented in 
some African nations, but surveillance is limited (The center for food science and public 
health, 2018). In Europe, B. suis biovar 2 has been isolated mainly from some immune-
compromised patients, it is a major cause of abortions, infertility, and economic losses in pig 
farms (Dieste-Perez et al., 2015). 
2.2.2 Transmission 
Most domesticated pigs are thought to acquire B. suis when they ingest feed or water 
contaminated by birth products (e.g., fetus, placenta, fetal fluids) or vaginal discharges from 
an infected sow, or eat dead fetuses and fetal membranes. Pigs also shed this organism 
in milk, urine, and semen. Both symptomatic and asymptomatic boars can excrete bacteria, 
and venereal transmission is common in swine. Piglets get infected during nursing or in 
utero (The center for food science and public health, 2018). Although the disease is 
associated with reproductive losses in swine worldwide, its primary concern is related to its 
zoonotic capability of causing clinical illness in humans. Addressing brucellosis in livestock 
reservoirs is the most efficient and economical approach for reducing human infections 




2.2.3 Clinical Signs 
 
In pigs, the most common clinical signs are reproductive losses, which may include 
abortions (The center for food science and public health, 2018), stillbirths, the birth of weak 
piglets (which may die early in life) from 100 to 110 days of gestation, and decreased litter 
size (Olsen and Tatum, 2017). Other signs include infertility, orchitis, inflammatory lesions 
in the joints, reproductive organs, paralysis of posterior limbs, and lameness 
(Kalleshamurthy et al., 2019). Metritis, infertility, and placental retention may be observed in 
infected sows (Olsen and Tatum, 2017). 
 
 
2.2.4 Treatment, prevention, and control 
 
Further studies need to be conducted since only one study reported that to clear B. suis one 
can use a combination of oxytetracycline and tildipirosin (The center for food science and 
public health, 2018). No commercial vaccine is currently used to control brucellosis in swine. 
The most effective approach although not always practical is the whole-herd depopulation 
(Olsen and Tatum, 2017). In an infected herd, the placenta, abortion products, and 
contaminated bedding should be removed and destroyed. Contaminated fomites should be 
disinfected.  Programs to eradicate this organism from a country also include movement 
controls on infected herds, surveillance, and tracing of infected animals (The center for food 
science and public health, 2018). 
 
2.3 Brucellosis in cattle 
Brucella abortus, the etiological agent, is a Gram-negative non-motile and non- sporulating 
bacterium that forms coccobacilli with oxidative metabolism (Gorofolo et al., 2017). Brucella 
abortus is found worldwide in cattle, with rare exceptions such as Iceland. Eradication 
programs in several European nations, Canada, Australia, New Zealand, Japan, and Israel 
have eliminated this organism from domesticated animals. The U.S. is also B. abortus free. 
Sporadic cases may be reported in travelers and immigrants in B. abortus-free countries 
(The center for food security and public health, 2018). 
Bovine brucellosis is a widespread zoonotic disease, endemic in some regions of the world 
namely Latin America, the Middle East, Africa, and Asia, and accountable for big economic 




government has conducted a countrywide eradication program for cattle brucellosis since 
1994. Animal cases are currently limited to seven regions of southern Italy, with the highest 
prevalence of infection in areas of Sicily, Calabria, and Apulia. This eradication program, 
along with strict regulations on cattle movements, has reduced the prevalence and 
geographic distribution of brucellosis in Italy (Gorofolo et al., 2017). Bovine brucellosis is 
endemic in all nine provinces of South Africa but particularly focused in the central and 
Highveld zones (Frean et al., 2018). Figure 2.2 shows the B. abortus outbreaks from January 
2015 to May 2018 as reported to the Directorate Animal Health of the Department of 
Agriculture, Forestry and Fisheries (DAFF). A recent outbreak was reported in KwaZulu 































Figure 2. 2: Reported Brucella abortus outbreaks in animals from January 2015 to May 
2018 across all nine provinces of South Africa. Image courtesy of the Epidemiology Sub-
Directorate of the Directorate Animal Health, Department of Agriculture, Forestry, and 






Cattle often acquire B. abortus by contact with organisms in vaginal discharges and birth 
products (e.g., placenta, fetus, fetal fluids) from infected animals. Ingestion and 
transmission through mucous membranes are the major routes, but organisms can also 
enter the body via broken skin (The center for food security and public health, 2018). 
Brucella abortus is a significant zoonotic agent, and humans are typically infected by 
consumption of raw dairy products, exposure to aerosolized bacteria at slaughter, or during 
veterinary care and animal husbandry (Gorofolo et al., 2017). 
 
2.3.2 Clinical Signs 
Abortions (typically during the second half of gestation), stillbirths, and the birth of weak 
offspring are the predominant clinical signs in cattle. Weak calves may die soon after birth. 
Signs of illness do not usually accompany uncomplicated reproductive losses; however, 
retention of the placenta and secondary metritis are possible complications. Epididymitis, 
seminal vesiculitis, orchitis, or testicular abscesses are seen in bulls. Infertility or reduced 
fertility occurs occasionally in both sexes, due to metritis or orchitis/epididymitis. Arthritis 
and hygromas may be seen, especially in long-term infections (The center for food security 
and public health, 2018). In cattle, the disease presents primarily as reproductive disorders 




2.3.3 Treatment, prevention and control 
There is no treatment for bovine brucellosis currently. Vaccination is an important 
inexpensive tool used in the control, management, and elimination of brucellosis, 
Nevertheless, vaccination alone is not sufficient for controlling and preventing brucellosis. 
It should be associated with test and slaughter policies, pasteurization of dairy products, 
surveillance, and hygiene procedures (Jezi et al., 2019). In general, the control programs 
of Brucella infection in cattle rely mainly on vaccination with live attenuated B. abortus strain 
19. This provides good levels of protection against B. abortus in cattle (Gwida et al., 2016). 
The improvement of a successful vaccine to eliminate brucellosis is still a task for scientists 
for years ahead. Regardless of the huge improvements with the development of current 




(Dorneles et al., 2015). Vaccination of animals is the most effective way of controlling and 
eradicating this zoonotic disease especially in high prevalence regions. Not consuming 
undercooked meat and unpasteurized dairy products and using protective gear when 
handling tissues are the best ways of preventing infection in humans (Jaff, 2016). 
The slaughtering and proper disposal of seropositive animals to decrease the incidence of 
infection in healthy animals and effective vaccination and hygienic practices would reduce 
the spread of the disease in/from endemic regions (Khan and Zahoor, 2018). 
 
 
2.4 Brucellosis in sheep and goats 
In sheep and goats, brucellosis is caused by Brucella melitensis, a Gram- negative 
coccobacillus or short rod in the family Brucellaceae (class Alphaproteobacteria) (The 
center for food security and public health, 2018). This organism is a facultative intracellular 
bacterium mostly associated with reproductive failure (Fiasconaro et al., 2015; Saxena et 
al., 2018). Brucella melitensis contains three biovars (biovars 1, 2, and 3). All three biovars 
cause disease in small ruminants, but their geographic distribution varies (Saxena et al., 
2018). Brucella melitensis is the most common and more virulent species causing human 
disease (Chota et al., 2016); with some estimates suggesting that, it is responsible for 70% 
of all infections. Most people acquire this organism by direct contact with infected animals 
or their tissues, or by the ingestion of contaminated dairy products. Brucella melitensis was 
eradicated in some countries, but it continues to cause significant losses from decreased 
productivity and lost trade in much of the developing world. In B. melitensis-free nations, 
the cost of surveillance to prevent its reintroduction is significant. There are also concerns 
that this organism is be used in a bioterrorist attack (The center for food security and public 
health, 2018). Infections in sheep and goats spill over into wild ruminants. However, there 
is no evidence that these animals serve as reservoir hosts for domesticated sheep and 
goats (Saxena et al., 2018). 
This organism is absent from domesticated animals in northern and central Europe, 
Canada, the U.S., Australia, New Zealand, Japan, and some other countries. Sporadic 
cases are sometimes reported in traveler and immigrants in B. melitensis - free nations 
(The center for food security and public health, 2018). Brucella melitensis is particularly 
common in the Mediterranean. It also occurs in the Middle East, Central Asia, around the 




This organism has been reported from Africa and India, but it does not seem to be endemic 
in Northern Europe, North America (except Mexico), Southeast Asia, Australia, or New 
Zealand. Biovar 3 is the predominant biovar in the Mediterranean countries and the Middle 
East, and biovar 1 predominates in Central America.  In the U.S., cases have mainly been 
reported in imported goats and rarely in cattle (Saxena et al., 2018). 
 
2.4.1 Transmission 
Brucella melitensis is shed when the animal aborts or carry the pregnancy to term, and 
reinvasion of the uterus can occur during subsequent pregnancies (The center for food 
security and public health, 2018). In animals, B. melitensis is transmitted by contact with the 
placenta, fetus, fetal fluids, and vaginal discharges from infected animals. Small ruminants 
are infectious after either abortion or full-term parturition. Goats usually shed B. melitensis 
in vaginal discharges for at least 2 to 3 months but shedding usually ends within three 
weeks in sheep. The organism is found the milk and semen; shedding in milk and semen 
can be prolonged or lifelong, particularly in goats. Kids and lambs that nurse from infected 
dams may shed B. melitensis in the feces (Saxena et al., 2018). 
 
2.4.2 Clinical Signs 
The predominant clinical signs in sheep and goats are abortions (most often during the last 
trimester), stillbirths, and the birth of weak offspring. Most animals abort only once, and 
subsequent pregnancies are usually normal. Reductions in milk yield are common. While 
mastitis was reported in small ruminants experimentally infected with large doses of B. 
melitensis, clinically apparent mastitis is uncommon in the field.  (The center for food 
security and public health, 2018).  Animals that abort may retain the placenta. Sheep and 
goats usually abort only once, but reinvasion of the uterus and shedding of organisms can 
occur during subsequent pregnancies (Alsaif et al., 2018). Some infected animals carry  
pregnancy to term but shed the organism. Milk yield is significantly reduced in animals that 
abort, as well as in animals whose udder become infected after a normal birth. However, 
clinical signs of mastitis are uncommon. Acute orchitis and epididymitis can occur in males 
and may result in infertility. Arthritis is seen occasionally in both sexes (Saxena et al., 2018). 
The infection causes inflammation of the male reproductive organs the epididymis in rams, 
resulting in infertility and sterility in some affected rams. In some flocks, over 50 percent of 




in ewes, and increased perinatal mortality (Animal Biosecurity and welfare, 2017.). 
2.4.3 Treatment, prevention, and control 
 
Antibiotics can mitigate the clinical signs, and a few studies have reported that treatment 
may have eliminated Brucella from small ruminants or cattle. However, even when the 
organisms seem to have disappeared, they might persist in lymph nodes or other tissues 
and re-emerge. In addition, none of the published treatments have been extensively 
evaluated (The center for food security and public health, 2018). There is no vaccine or 
other preventive treatment available, and infected rams cannot be cured. Eradication of the 
disease from infected flocks requires identification of infected rams and culling them (Animal 
Biosecurity and welfare, 2017). 
The control programs of Brucella infection in animals rely mainly on vaccination with live 
attenuated B. melitensis Rev 1. This provides good levels of protection against B. melitensis 
in sheep and goats (Gwida et al., 2016). This vaccine also interferes with serological tests, 
particularly when injected subcutaneously, but conjunctival administration to lambs and 
kids between the ages of 3 and 6 months minimizes this problem (Saxena et al., 2018).  
Programs to eradicate this organism from a country also include movement controls on 
infected herds, surveillance, and tracing of infected animals (The center for food security 
and public health, 2018). 
 
2.5 Brucellosis in dogs 
Brucella canis is a gram-negative coccobacillus bacterium that primarily causes 
reproductive failure in dogs (Hensel et al., 2018). Brucella canis is an important cause of 
reproductive failure in dogs, especially in kennels (The center for food security and public 
health, 2018). The organism is an intracellular bacterium found in breeding kennels. 
Brucella canis infection causes a zoonotic disease that can infect humans (Bramlage et al., 
2015). It is a worldwide disseminated disease and highly resistant to antibiotic therapy 
mainly due to its intracellular location (Pujol et al., 2019). However, human infections with 
this organism may be under-diagnosed, as the symptoms are nonspecific, diagnostic 
suspicion among physicians is low, and obtaining a definitive diagnosis may be difficult 
(The center for food security and public health, 2018). 




South America and parts of Asia, Africa, and Europe. New Zealand and Australia appear 
to be free of B. canis (The center for food security and public health, 2018). It has a 
ubiquitous distribution and is  reported in the United States, Canada, Central, and South 
America, Tunisia, South Africa, Nigeria, Madagascar, Malaysia, India, Korea, Japan, and 
China among others (Ayoola et al., 2016). Few studies have been conducted to evaluate 
disease occurrence and distribution in the United States, so the status is unknown. 
However, in the past 2 decades, serologic studies of dogs have been published from 
countries in Africa, Asia, and South America and have reported moderate to high 
seroprevalence, ranging from 6% to 35% (Hensel et al., 2018). 
2.5.1 Transmission 
 
Thie organism is shed in urine, and low concentrations of bacteria has been detected in 
saliva, nasal and ocular secretions, and feces. In dogs, B. canis primarily enters the body 
by ingestion and through the genital, oronasal, conjunctival mucosa, and transmission 
through broken skin may be possible. Most cases are thought to be acquired venereally 
(including via artificial insemination) or by contact with the fetus and fetal membranes after 
abortions and stillbirths (The center for food security and public health, 2018). Brucella 
canis infection in dogs occurs predominantly through ingestion, inhalation, or contact with 
aborted fetuses or placenta, vaginal secretions, or semen. Infected dogs intermittently shed 
low concentrations of bacteria in seminal fluids and non-estrus vaginal secretions (Hensel 
et al., 2018). Transmission of Brucella infection in dogs occurs via ingestion of 
contaminated materials or venereal routes. It can be easily transmitted among dogs reared 
intensively in breeding kennels or where owners rear two or more dogs (Ayoola et al., 2016). 
Brucella canis organisms are shed in the highest numbers in aborted material and vaginal 
discharge. Infected females transmit canine brucellosis during estrus, at breeding, or after 
abortion through oronasal contact of vaginal discharges and aborted materials (Bramlage 
et al., 2015). 
 
2.5.2 Clinical Signs 
In females, early embryonic death may lead to resorption and result in perceived 
conception failure whereas in males, B. canis usually infects the prostate, testicles, and 
epididymis, and clinical signs are associated with these areas. Enlargement of one or both 




- to late-term abortion (days 45–59 of pregnancy), followed by an odourless, brown-to-
yellow vaginal discharge for 1–6 weeks. Another manifestation is embryonic death with 
resorption, which appears as conception failure after successful mating (Hensel et al., 
2018). The clinical manifestation of the disease in dogs includes abortion, infertility, orchitis, 
epididymitis, and testicular atrophy (Ayoola et al., 2016). Infected dogs have a history of 
lameness, spinal pain, neurologic dysfunction, muscle weakness, or any combination of 
these signs, caused by vertebral osteomyelitis and intervertebral disc infection (Hensel et 
al., 2018). Most abortions occur during the last trimester, especially between 45 and 55 
days, and typically have no significant premonitory signs. Abortion is usually followed by a 
mucoid, serosanguinous, or gray-green vaginal discharge that persists for several weeks. 
Early embryonic deaths and resorption are usually reported a few weeks after mating and 
may be mistaken for failure to conceive. Reproductive losses recur during subsequent 
pregnancies in some dogs, but not in others. Such recurrences may be intermittent (The 
center for food security and public health, 2018). 
 
2.5.3 Treatment, prevention, and control 
Antimicrobial drug treatment alone after signs of reproductive failure is usually 
unsuccessful because of the ability of the bacteria to sequester intracellularly for long 
periods and cause episodic bacteraemia. The recommended course of treatment is 
multimodal and includes surgical sterilization and antimicrobial drugs (Hensel et al., 2018). 
No treatment is certain to eliminate B. canis, and recrudescence is possible. Even when 
this organism seems to have disappeared, it may persist in tissues such as the lymph 
nodes, spleen, uterus, and prostate. For this reason, euthanasia of infected animals is often 
recommended in kennels, and this option should be discussed when B. canis is found in a 




In infected kennels, brucellosis is controlled by sanitation and infection control measures, 
together with the euthanasia, isolation, or removal of infected dogs. Housing in individual 
cages reduces the spread of the organism (The center for food security and public health, 
2018). 
 
2.6 Pathogenesis of brucellosis 
Brucella spp cause the disease but requires a significant process during infection (Poester 
et al., 2013). Macrophages in the intestine are a portal of entry for Brucella spp. Epithelial 
cells can be invaded by Brucella spp and allow an infection to go through mucosal surfaces. 
Once the Brucella spp succeed in invading, they can survive intracellular in phagocytic or 
non-phagocytic host cells (Luelseged et al., 2018). Brucella spp are capable of interfering 
with intracellular traffic, preventing the fusion of the Brucella-containing vacuole (BCV) with 
lysosome markers, and directing the vacuole to a section that has rough endoplasmic 
reticulum (RER), which is extremely tolerant to intracellular duplication of Brucella (Poester 
et al., 2013). A successful entry of Brucella into the host is a crucial step in establishing 
infection. Considering that the digestive tract is the main entrance route of Brucella, some 
studies investigated possible virulence factors involved in successful infection through the 


























As shown in Figure 2.3, the entry of Brucella bacteria is through macrophages and 
subsequently, the bacteria are taken up by macrophages of the mucosa-associated 
lymphoid tissue (MALT). These macrophages transport the bacteria to the lymph nodes 
and on to systemic sites. Blown-up macrophage shows trafficking within the macrophage 
from entry via lipid rafts, through the endosomal pathway to the ER-like compartment in 
which Brucella replicates. In red are Brucella virulence factors that are involved in 
establishing infection (Xavier et al., 2010). 
 
Table 2. 3: Animals affected by Brucella species (DAFF, 2016). 
Host B. abortus B. melitensis B. suis B. canis B. ovis 
Cattle + + +(rare) - - 
Buffaloes + + - - - 
Bison + - - - - 
Sheep +(rare) + +(possible) - + 
Goats +(rare) + - - - 
Swine +(rare) + + - - 
Dogs + + +(rare) + - 
Camels +(rare) + - - - 
Caribou/Reindeer - - +(biovar 4) - - 
Elk + - - - - 
Horses + +(rare) +(rare) - - 
Rodents +(rare) +(rare) +(biovar 5) - - 
 
 
The recently recognized types associated with marine animals, B. ceti and B. pinnipedialis, 
may also have the capacity to cause human disease (Amjadi et al., 2019). Recent isolates 
from humans (B. inopinata), aquatic mammals (B. pinnipedialis and B. ceti), and a common 
vole (B. microti) are recognized as new species, bringing the current number to 10 species 
in the genus (de Figueiredo et al., 2015).  Brucella bacterium is divided into two categories, 
rough colony, and smooth colony, based on lipopolysaccharide (LPS) expression listed in 
table 2.4.  Smooth species, fully expressing the O-chain, are more virulent than the rough 




Table 2. 4: Genus Brucella (Young, 2012). 
Species Biovar(s) Host(s) Human 
pathogen 
B. melitensis 1-3 Goats, sheep Yes 
B. abortus 1-6,9 Cattle Yes 




5 Rodents Yes 
B. neotomae - Desert wood 
Rats 
No 
B. ovisa - Sheep No 
B. canis - Dogs Yes 
a signifies naturally rough strains (lacking O-polysaccharide). 
 
2.7 Diagnostic assays for brucellosis 
 
2.7.1 The Rose Bengal Test 
 
The Rose Bengal Test is used as a rapid screening test and is considered a reliable test in 
the diagnosis of brucellosis (Saxena et al., 2018).  It is a simple spot agglutination test using 
antigen with Rose Bengal dye and buffered to a low pH, usually 3.65 ± 0.05 (WHO, 2013). 
The RBT can show false-positive results because of S19 vaccination or non-specific 
serological reactions (Kangumba, 2015).  It is quick, cheap, and easy to perform 
(Delegates, 2016).  According to a study conducted by Geresu and Kassa (2016), RBT has 
some disadvantages of low sensitivity particularly in chronic cases, relatively low specificity 
in endemic areas and prozones that make strongly positive sera test negative. The Rose 
Bengal Test is an agglutination test that detects anti-Brucella antibodies in serum.  It is a 
rapid and sensitive test and acts as a good screening test for bovine serum samples 






2.7.2 Complement fixation test 
The Complement fixation test is based on the ability of complement (obtained from guinea 
pig serum) to lyses erythrocytes (traditionally sheep erythrocytes sensitized with hemolysin) 
in the absence of an antibody-antigen complex (Pérez-Sancho et al., 2015). The CFT is 
widely used but it is complex to perform, the accuracy of titration and maintenance of 
reagents require enough specialized personnel to perform the test in the laboratory facility 
(WHO, 2016). The  test is used for the diagnosis of various bacterial and protozoal diseases. 
When Brucella-specific antibodies are present in the serum being analysed, they bind to the 
Brucella antigens (whole cells) provided externally, forming antigen-antibody complexes that 
then bind to the complement (Perez-Sancho et al., 2015).  The CFT is sensitive, specific, 
and used as a confirmatory test for testing of individual animals (Minas A et al., 2005).  
 
2.7.3 Fluorescence polarization assay 
 
Fluorescence Polarization Assay is established on the principle of spinning molecules in a 
liquid medium correlating with their mass. The method is rapid and depends on serological 
instrument that provides an alternative to conventional serology and has been included in 
routine testing elsewhere (Mahmood et al., 2015). The FPA test is simple, quick, and easy 
to perform and gives rapid results. Furthermore, it is expected to be highly reproducible 
across laboratories and instruments and reduces human error and variability that may occur 
during the reading of agglutination tests result such as the card test, the standard plate test, 
and other similar tests (Kangumba, 2015). 
 
The mechanism of the assay is based on the use of a fluorescence polarization analyzer to 
measure the reduced rate of rotation of large molecules in solution, such as antigen-antibody 
complex, which may be present in blood sera from infected animals (Fiasconaro et al., 
2015).  A fluorochrome-labeled antigen of small molecular weight is added to serum or other 
fluid to be tested. If the antibody is present, attachment to the labelled antigen will cause its 




CHAPTER 3: MATERIALS AND METHODS 
 
3.1 Source of samples 
Blood samples that were collected by Gauteng Department of Agriculture and Rural 
Development were used for the project. Blood samples were from known positive and 
negative herds and submitted to the Bacterial Serology laboratory at the Agricultural 
Research Council (ARC), Onderstepoort Veterinary Research (OVR) in Pretoria. These 
samples were from cattle reared by commercial and non- commercial farmers. The period 
of collection covered September 2018 to April 2019.  
3.2 Ethical clearance 
The College of Agriculture and Environmental Science and Health Research Ethics 
committee of the University of South Africa provided ethics clearance (2018/CAES/075) for 
this research (Appendix A). The Onderstepoort Veterinary Research issued an approval 
letter for the research project and ethical clearance letter (Appendices B and C). The 
permission to access samples collected by Gauteng veterinary service was obtained from 
the Gauteng Department of Agriculture and Rural Development, State Veterinary Pretoria 
(Appendix D).  Section 20 permit to purchase the Brucella FPA test kit was issued by the 
Director of Animal Health from the Department of Agriculture Forestry and Fisheries in 2018 
(Appendix E). 




3.3 Study population and sampling 
 
The study was conducted in Pretoria, the administrative capital of South Africa, located in 
Gauteng province, with an estimated population of 15, 488,137 (2020). Samples were 
tested at the Agricultural Research Council (ARC) laboratory, Onderstepoort Veterinary 
Research. The study population comprised vaccinated and unvaccinated cattle from 
commercial and non-commercial farmers.  Herds that had many serological reactors with 
several high titers were classified as serologically positive while those with no reactions on 
RBT and SAT were classified as negative.  Samples were categorized into positive and 
negative sera and stored separately. The serum samples were stored in the refrigerator at 
4°C ± 2 ºC until processed.  In total, 493 positive serum samples and 532 negative serum 
samples from 1025 female cattle were used for this study. 
 
Table 3. 1: The total number of positive samples collected was 493. 
Farm name District/Municipality Samples collected 
Herd 1 Kungwini Bronkhorstspruit 
local municipality 
108 
Herd 2 Randfontein local 
Municipality 
13 
Herd 3 Ekurhuleni Boksburg local 
Municipality 
98 
Herd 4 Kungwini Bronkhorstspruit 
local municipality 
9 
Herd 5 Kungwini Bronkhorstspruit 
local municipality 
140 
Herd 6 Randfontein Krugersdorp 
local municipality 
29 
Herd 7 Merafong local municipality 38 
Herd 8 Ekurhuleni local municipality 58 




Table 3. 2: The total number of negative samples collected was 532. 
Farm name District/municipality Samples collected 
Herd A Sedibeng local municipality 116 
Herd B Kungwini Bronkhorstspruit 
local municipality 
117 
Herd C Kungwini Bronkhorstspruit 
local municipality 
112 
Herd D Merafong fochville local 
municipality 
60 
Herd E Kungwini Bronkhorstspruit 
local municipality 
63 
Herd F Pretoria Tshwane local 
Municipality 
11 
Herd G Randfontein Krugersdorp 
local municipality 
31 
Herd H Midvaal local municipality 22 
Total  532 
 
 
 3.4 Preparation of blood samples for analysis 
Blood samples were centrifuged for 10 minutes at 3220-rpm speed to get the clear serum. 
The serum samples were then marked, aliquoted in Nunc tubes and stored at 
4°C ± 2 ºC in the Serology laboratory refrigerator. 
 
 3.5 Data analysis 
All data were entered manually into a Microsoft Excel spreadsheet, and data cleaning and 
analysis were carried out using a statistical package for the social sciences (SPSS) version 
26 and Graph pad Prism version 9 software. 
The cut-off value for FPA that gives the highest sum of DSn and DSp values and the area 
under curve (AUC) and their 95% CI were determined from the analysis of results of negative 
reference sera (532 sera) and positive reference sera (493 sera). Receiver operator 
characteristic (ROC) analysis of the results were carried out using the same software. 
The DSn, DSp, Youden’s J value and AUC and their 95% confidence interval (CI) of every 
test used in the study were calculated with cross-tabulation and ROC analysis of the results 
for reference sera classified negative based on negative reactions on RBT and SAT and 




positive reactors on serological testing with several high titers. The agreement of test 
results was assessed with the analysis of the results of all sera tested in brucellosis free 
and infected flocks (n=1025), by Kappa analysis and calculation of Kappa (K) statistic. The 
performance of the tests used were compared by Friedman test for repeat measurements. 
3.6 Serological tests 
3.6.1 Rose Bengal Test 
The Rose Bengal reagent used for the study contains Brucella abortus biovar 1 
(Weybridge 99 strain) inactivated by heat and phenol, coloured with Rose Bengal stain, 
and diluted in an acidified buffer. The Brucella abortus Rose Bengal Test Onderstepoort 
Biological Products antigen (obtainable from Onderstepoort Biological Products, VLA, and 
IDEXX Pourquier) was stored at 4 ±3˚c.  An equal volume (25 µl) of Rose Bengal antigen 
and serum were mixed in haemagglutination plates (180x180 mm containing 100 
hemispherical wells 15mm in diameter). The plates were tapped gently on each side to 
ensure that the serum mixes properly with the antigen in the wells.  The plates were placed 
on the shaker; set at 40-rpm speed for 4 minutes.  The source of positive control was 
Onderstepoort National Standard manufactured by Onderstepoort Biological Products. 
The method for preparation of the positive control was already done according to the OIE 
Terrestrial Manual 2019.  The lifespan of the prepared positive control is 1 year.  The 
serum was stored at -20-˚C ±10˚C in small aliquots and brought to room temperature 
before use as per OIE procedure (2013). 
The plates were read using the UV lightbox (Figure 3.1) 
 
The well was read as positive in the presence of any ringing or agglutination or as negative 























Figure 3. 1: Reading and recording of RBT results on the BR5 form. 
3.6.2 Complement Fixation Test 
 
The following reagents were used for CFT: 
• Brucella abortus complement antigen (supplied by Onderstepoort Biological 
Products) 
• Brucella abortus standardized positive control (supplied by Onderstepoort 
Biological Products) 
• Brucella abortus negative control (made in the laboratory) 
• Guineapig Complement for CFT (supplied by Virion serian product – Kat medical) 
• Amboceptor from rabbit (supplied by supplied by Virion serian product – Kat 
medical) 
• CFT buffer (made in the laboratory) 
• Sheep red blood cells (Bled by the laboratory and send to Western Cape 
laboratory to test and used if negative). 
• Test sera (supplied by different animal health technicians from the State 
veterinarian) 







Procedure: The 96 well U-bottom microtitre plates were marked according to the standard 
layout provided in the laboratory at OVR.  One hundred µl of each serum was dispensed 
into the respective wells according to the lab numbers.  The whole H- row was for the 
positive and negative controls.  One hundred µl of the positive and 100 µl of negative 
control was added in the appropriate wells starting with the positive control. 
Then plates were sealed using a plastic film. Test sera, positive and negative controls were 
inactivated by heating at 58 ºC ± 2 ºC for 30 minutes in a hot-air oven. The prepared plates 
were separated into two and marked as anti-complementary plates and as test plates. 
Twenty-five µl of buffer was dispensed in each well of both anti-complementary and test 
plates. Serum dilution was performed by taking 25µl of serum and diluting in the anti- 
complementary, and then diluting again to the test plate discarded. The anti- 
complementary had 25µl of buffer and 25µl complement. The test plate had 25µl of diluted 
serum, 25µl of antigen, and 25µl of complement. The test plate consists of antigen and 
anti-complementary. The test plate and anti-complementary plates were incubated for 30 
minutes at 38 ± ºC.  After 30 minutes, 3% of 50µl formalitic system blood was added to the 
test plate and incubated for 30 minutes in the shaker. After the process was done, the test 
and anti-complementary plates were centrifuged at 450-rpm speed for 3 minutes. Using a 
magnifying mirror or lightbox, the plates were read, and results recorded in the Brucella 
abortus CFT daily form and in the CA5 form (OIE Terrestrial Manual, 2013).  CFT results 
were read as follows. 
1. For negative result, there was no sedimentation of SRBC, only complete 
hemolysis. 
2. For positive result, there was sedimentation of SRBC as a distinct button at the 
bottom of the well. The sedimentation was scored between 1 and 4. The final 
dilution was determined as the dilution showing more than 0% hemolysis and was 





3. The anti-complementary well should be negative, otherwise, the test for the 
serum must be repeated (with and without antigen) or the results recorded as anti-
complementary. 
4. The positive control on each plate should give the correct titer (± 2 IU titers on 
each side are still acceptable). The negative control should always be negative. 
Interpretation of CFT test results: 
1. 0 = 100% haemolysis of SRBC. No button/pellet of SRBC at bottom, 
uniformly red supernatant. 
2. 1 = 75% haemolysis of SRBC. Small button/pellet of SRBC at bottom of 
well, lighter supernatant. 
3. 2 = 50% haemolysis of SRBC. Bigger button/pellet of SRBC medium red 
supernatant midway between 0 and 4. 
4. 3 = 25% haemolysis of SRBC. Still bigger/pellet of SRBC still lighter, 
almost clear supernatant. 
5. 4 = 0% haemolysis of SRBC. Large button/pellet of SRBC, supernatant 

























Figure 3. 2: CFT testing plate displaying negative and positive samples. Positive result is 




negative result is where no sedimentation of SRBC is present meaning that there is complete 
haemolysis. 
3.6.3 Fluorescence polarization assay 
The Fluorescence Polarization assay was performed using a Brucella abortus antibody test 
kit which uses Fluorescence Polarization technology designed to determine the presence 
of antibodies to Brucella abortus in bovine serum.  The reagents used in this assay were 
manufactured by Diachemix LCC, DOO biotehnika IVD Kraljevo Serbia, and supplied by 
Prionics AG Wagistrasse 27A CH- 8952 Schlieren, Switzerland.  The entire FPA assay was 
done in 96 well black flat-bottom microtiter plates (type COS96fb manufactured by Corning 
USA) with no precipitation or washing steps and the adding of only one reagent, the 
conjugate, was required.  
 
Initially, 20 µl of the controls and samples were dispensed to the wells of a black 96- well 
microtiter plate.  The negative controls were dispensed to wells A1, B1, C1, the positive 
control to well D1, and the test samples to the remaining wells. A volume of (180 µl) of 
diluted reaction buffer (1/24) was added to all wells containing controls and samples. The 
dilution buffer was provided by the manufacturer in 25x concentrate and was diluted by 
adding 24 parts of distilled water to 1 part of 25x concentrate. The diluted reaction buffer 
was free of particles and was stored at room temperature for one month. Buffer and serum 
samples were mixed, in the microplate on a rotating microplate shaker set at 600 rpm for 2 
minutes at room temperature. This was followed by letting the plate to stand for a minute. 
After the initial mixing, a background reading on samples and controls was taken at 
fluorescence polarization mode by a multi-mode Microplate reader (Prionics AG- 
PHERAstar Fluorescence polarization reader) connected to a desktop computer.  Then 
10 µl of the conjugate (tracer) was added to all the wells containing controls and samples, 
followed by mixing on a microplate shaker at 600 rpm for 2 minutes at room temperature. 
After letting the plate stand for a minute, a second reading was taken using the FPA 
reader. The reader automatically subtracted the background reading and calculated a 




The fluorescence polarization reader was calibrated using blank and low polarized 
standards, which were included in the kit together with the antigen. The calibration was 
done  automatically; the instrument takes the value of the low polarized standard (fixed at 
25 mP) and calculates an internal compensation factor (G-factor 0.850) which is utilized in 
the equation for calculating the results.  The results of each microplate measurement were 
accepted if the mP value of the positive control was 120-250 mP and the negative control 
read between 70– 90 mP. 
Equipment used included FPA PHERAstar Fluorescence polarization reader (96-well 
format), 96-well black flat-bottom microtiter plates, pipettes (10µl, 20µl, 180µl) disposable 










Figure 3. 3: FPA equipment and reagent 
The interpretation of the test is as follows: 
Negative: < 10mP 
Suspect: 10-20mP 
Positive: > 20 mP 
The yellow block indicates that the reaction of the test sample is suspect. The white 
indicates a negative reaction. All the remaining blue ones are positive reactors as show in 
figure 3.4. 
























































































































77 1 45 33 88 1 60 8 43 64 66 41 
77 17 11 148 167 74 112 66 8 20 133 99 
76 -2 146 139 83 91 32 21 25 95 91 38 
240 7 8 170 152 130 136 60 10 75 104 80 
52 47 -1 120 149 15 1 25 33 6 1 33 
59 34 51 91 36 41 64 0 30 115 15 48 
































Figure 3. 4: Results display in an excel worksheet. 
 
3.7 Determination of the specificity of the FPA 
The specificity of the FPA is the number of animals without the disease who will have a 
negative test result out of the total number tested, that is, 
DSp = [(True Negatives (TN) / (TN + False Positives (FP))] x 100. Specificity was 
estimated in Brucella-free herds by testing animal populations known to be free of the 
disease and testing negative, that is Dsp = animal testing negative/total number of animals 









3.8 Determination of the sensitivity of the FPA 
The sensitivity of FPA is the number of animals with the disease who will have a positive 
test result out of the total number tested, that is, DSe= [(True Positives (TP) 
/ (TP + False Negatives (FN))] x 100. Sensitivity was estimated in Brucella positive known 
herds by testing animal population known to have the disease and testing positive, that is, 
DSe = animal testing positive/total number of animals tested. Sensitivity is the fraction of 
those with the disease that had a positive test result. 
3.9 Determination of the reproducibility of FPA 
Reproducibility was determined through inter-laboratory testing by testing the same 
samples with a different laboratory and comparing them to see if they can produce the same 
results. Allerton Provincial Veterinary laboratory (APVL) participated in the inter-laboratory 
testing. Onderstepoort veterinary research sent samples and instructions to Allerton 
Provincial Veterinary Laboratory. Samples were packaged in Nunc tubes to avoid damage 
during transportation. The time between dispatch of samples and receipt of laboratory 
results was limited to one month. Allerton Provincial Veterinary Laboratory used the same 
approach as described under the section on determination of repeatability (3.11). 
After testing APVL sent their excel results sheet to OVR.  All results were received and 
recorded.  OVR was responsible for the data entry and checking for the preparation of the 
interim and final reports. The calculation was determined through Friedman and kappa 
tests. 
3.10 Determination of repeatability of FPA 
For repeatability, positive cattle serum samples (n = 15) and negative cattle serum samples 
(n=5) that were submitted for routine testing by Pretoria and Germiston State Veterinary 
offices were used. The sera included a variety of titers from low to high. The ranges for the 
low samples were from 24-49 IU per ml, medium 60-199 IU per ml and high from 240-784 
IU per ml. Three analysts tested the samples on three different days. The calculations were 
determined through kappa and Friedman tests. 
 
3.11 Determination of RBT and CFT limit of the lowest detection 




microliters of positive control were added, and dilution started from the first row until the 
last well. Twenty-five microliters of negative control were added in row 2 and diluted until the 
last well. Twenty-five microliters of serum were dispensed from the third row to the fifth row 
and diluted as with the controls. New tips were used for each dilution. Twenty-five 
microliters of B. abortus Rose Bengal Test antigen was added to all wells and the plates 
put on a shaker; set at 40-rpm speed for 4 minutes. Agglutination was an indication of positive 
reaction.   
For CFT the dilution was carried out as normal by picking up 25 µl of serum from the test 
plate using a hand-held 8-channel micropipette and delivering into row of the A/C plate. 
Twenty-five microliters from row 1 of the A/C plate was picked up and delivered to row 1 of 
the test plate. Twenty-five microliters from row 1 of the test plate row 1 was picked up and 
delivered to row 2 of the test plate. Serial dilutions were continued to row 6 of the test plate. 
Twenty-five microliters from row 6 was picked and discarded. This accomplished a ½ serial 
dilution of ¼, 1/8, 1/16, 1/32, 1/64 and 1/126 into row 6. The procedure was repeated for 
row 2 of the sera, delivering to row 2 of the A/C plate and diluting row 7-12 of the test plate. 
New tips for each batch of 8 sera were used. Fifty µl component/ CFT diluent (C’/2) was 
dispensed into the A/C plate. Fifty microliters C’/Ag was dispensed into the test plates. The 
plates were tapped gently to ensure mixing and incubated at 37˚C ± 2˚C 30 minutes.  
Fifty microliters haemolytic system (mixed well) was dispensed into all wells of both the test 
plate and the A/C plate and incubated at 37˚C ± 2˚C for 30 minutes on a shaker, avoiding 
stacking of the plates. The plates were removed from the incubator and centrifuged at a 
maximum of 450 RCF ±15 RCF for 3 minutes. Reading took place by recording the 
sedimentation of the SRBC as positive and complete haemolysis as negative.  
3.12 Determination of FPA turnaround time 
The turnaround time was calculated from the time used to set up an assay until test results 
were obtained. The time used by the different experiences of individuals in the same setting 
was compared. Forty positive cattle serum samples were used in this experiment. A routine 
maintenance and quality control evaluation was conducted before the initiation of sample 
tests run. The researcher after having been trained was able to carry test runs for FPA, 
RBT, and CFT. The average time to complete each test was considered as the turnaround 





CHAPTER 4: RESULTS 
 
A total number of 493 positive samples were from herds that had many serological 
reactors with several high titres and were classified as serologically positive herds. Among 
493 only 400 tested positive for RBT, 19 tested negative and 74 samples were invalid, 368 
tested positive for CFT, 51 tested negative and 74 samples were invalid. The number of 
samples testing positive with FPA was 379, with 23 testing negative and the other 17 were 
suspects. Furthermore, 74 samples were invalid due to insufficient tracer dispensed in the 
wells. The serology gold standard for brucellosis, the complement fixation test CFT was 
compared with FPA as a confirmatory serological diagnosis of brucellosis. Tables 4.1 and 
4.2 below show summarized results of serological examination. 
 
4.1 Brucellosis tests per herd for the positive and negative samples 
 






RBT+ve RBT -ve CFT+ve CFT-ve FPA+ve FPA -ve 
Herd 1 108 87 21 55 32 74 34 
Herd 2 13 13 0 13 0 13 0 
Herd 3 98 98 0 98 0 95 3 
Herd 4 9 9 0 9 0 9 0 
Herd 5 140 140 0 140 0 137 3 
Herd 6 29 29 0 29 0 26 3 
Herd 7 38 38 0 38 0 38 0 
Herd 8 58 58 0 58 0 25 33 





A total number of 532 negative samples from herds that were classified negative based on 
negative results on RBT and SAT. Among 532 only 445 tested negatives for RBT, and 87 
samples were invalid. Four hundred and eighteen tested negatives with FPA, 10 were 
positive 17 were suspects and 87 were invalid samples. 
 






RBT+ve RBT -ve FPA +ve FPA –ve 
Herd 1 116 0 116 9 107 
Herd 2 117 0 117 13 104 
Herd 3 112 0 112 0 112 
Herd 4 60 0 60 1 59 
Herd 5 63 0 63 0 63 
Herd 6 11 0 11 0 11 
Herd 7 31 0 31 0 31 
Herd 8 22 0 22 1 21 
Total 532 0 445 10 418 
 
 
4.2 Sensitivity of the FPA 
The sensitivity of FPA was determined by the ROC curve analysis. 
 
Table 4. 3: Positive Roc analysis. 
FPA 
  Frequency Percent Valid Percent Cumulative 
Percent 
Valid Suspect 17 4,1 4,1 4,1 
 Negative 23 5,5 5,5 9,5 
 Positive 379 90,5 90,5 100,0 







Area under the ROC curve  
Area 0,9842 
Std. Error 0,005532 
95% confidence interval 0,9733 to 0,9950 
P value <0,0001 
  
Data  
Controls (mpValue) 419 
Patients (Results) 419 
Missing Controls 74 
Missing Patients 74 
 
 
Youden J statistic 






95% CI Specificity 
% 




95,94 93,60% to 
97,45% 
0,000 0,000% to 
0,9085% 
0,9594 
> 0.5000 90,45 87,26% to 
92,91% 









Figure 4. 1: ROC curve diagram of FPA using positive reference sera originating from 






Table 4. 4: DSn and DSp of FPA at different cut-off values calculated by ROC analysis using 
as positive reference sera with positive results in two serological tests in parallel. 
 
mpValue Sensitivity% 95% CI Specificity% 95% CI Likelihood ratio 
< 79.00 100 99,09% to 100,0% 73,51 69,08% to 77,51% 3,775 
< 81.50 100 99,09% to 100,0% 73,27 68,83% to 77,28% 3,741 
< 83.50 100 99,09% to 100,0% 73,03 68,59% to 77,06% 3,708 
< 85.00 100 99,09% to 100,0% 72,79 68,34% to 76,83% 3,675 
< 87.00 100 99,09% to 100,0% 72,55 68,09% to 76,61% 3,643 
< 88.50 100 99,09% to 100,0% 72,32 67,84% to 76,38% 3,612 
< 90.00 100 99,09% to 100,0% 71,84 67,35% to 75,93% 3,551 
< 92.00 100 99,09% to 100,0% 70,64 66,11% to 74,80% 3,407 
< 93.50 100 99,09% to 100,0% 70,41 65,87% to 74,58% 3,379 
 
 
4.3 Specificity of the FPA 
 
The specificity of the FPA is the fraction of samples from animals without the disease, 
which test negative. Specificity was estimated in Brucella-free herds by testing animal 
populations (n=415) had tested negative and were known to be free of the disease 
(n=25) using a ROC curve analysis. 
 
Table 4. 5: ROC Negative analysis. 
FPA 




Valid Suspect 17 3,8 3,8 3,8 
 Negative 418 93,9 93,9 97,8 
 Positive 10 2,2 2,2 100,0 
 Total 445 100,0 100,0  
 
 
Area under the ROC curve  
Area 0,9888 
Std. Error 0,004082 
95% confidence interval 0,9808 to 0,9968 
P value <0,0001 
  
Data  




Patients (FPA) 445 
Missing Controls 87 
Missing Patients 87 
 
 
Youden J statistic 




































      
 
Figure 4. 2: ROC curve diagram of FPA using negative reference sera originated from 
animals that were confirmed negative in RBT and SAT. 
4.4 Reproducibility of FPA 
Reproducibility was determined through inter-laboratory testing between Allerton 
laboratory and Onderstepoort Veterinary laboratory. Allerton Provincial Veterinary 
Laboratory tested their samples using a Synergy H1 Microplate instrument with injectors 
using Brucella FPA kit, which seems to be more rapid. Dispensation into wells was done 
automatically as well as calculations by Gen 5 software, while Onderstepoort ran the test 
using the previous version of the PHERAstar plate reader connected to the computer 




calculation of results. Table 4.6 shows how the results were interpreted after subtraction 
of the negative mP value from the sample mP value. Delta mP gives the final reading that 
determines whether the sample is positive or negative. 
 
Table 4. 6: Reproducibility of FPA Positive and negative. 
Allerton * OVR Crosstabulation 
      Total 
Allerton 
     
5 
   Expected 
Count 
1,5 3,5 5,0 
1.00  Count 1 14 15 
   Expected 
Count 
4,5 10,5 15,0 
Total   Count 6 14 20 
   Expected 
Count 
6,0 14,0 20,0 
 
Symmetric Measures 
  Value Asymptotic 
Standard 
Errora 




Kappa 0,875 0,121  3,944 0,000 
 




    
 
 
Table 4. 7: Positive and negative Friedman Test. 
Descriptive Statistics 
N 
Allerton 20 0,2500 1,0000 1,0000 
OVR 20 0,0000 1,0000 1,0000 
 
Friedman Test: Ranks 
Mean Rank 
Allerton    1,53 





N    20 
Chi-Square    1,000 
df    1 
Asymp. Sig.    0,317 
a. Friedman Test     
 
 
4.5 Repeatability of FPA 
 
For repeatability, positive cattle serum samples (n = 15) and 5 negative samples that were 
stored at Onderstepoort were used. The sera included a variety of titters from the lowest 
to the highest titter. The ranges for the low samples ranged from 24-49 IU per ml, medium 
60-199 IU per ml and high from 240-784 IU per ml. Three analysts analyzed the same 
samples on the same day under the same conditions. The test was performed on 3 different 
days using the same reagents every time. 
 
Table 4. 8: Repeatability of FPA Positive and negative Onderstepoort Analyst 1 day 1, 
Analyst 1 day 2 and Analyst 1 day 3. 
 




P value 0,2636 
Exact or approximate P value? Approximate 
P value summary Ns 
Are means significantly different? (P < 0.05) No 
Number of groups 3 
Friedman statistic 2,667 
Data summary 
 
Number of treatments (columns) 3 
Number of subjects (rows) 20 









Multiple comparison of Analyst 1 day 1, Analyst 1 day 2 and 
Analyst 1 day 3 
Multiple comparison 
      
Number of families 1      
Number of comparisons 
per family 
3      







Summary Adjusted P 
Value 
  
Analyst 1 day 1 vs. 
Analyst 1 day 2 
0 No ns >0,9999 A- 
B 
 
Analyst 1 day 1 vs. 
Analyst 1 day 3 
-3 No ns >0,9999 A- 
C 
 
Analyst 1 day 2 vs. 
Analyst 1 day 3 
-3 No ns >0,9999 B- 
C 
 






n1 n2 Z 
Analyst 1 day 1 vs. 
Analyst 1 day 2 
39 39 0 20 20 0 
Analyst 1 day 1 vs. 
Analyst 1 day 3 
39 42 -3 20 20 0,474 
3 
Analyst 1 day 2 vs. 
Analyst 1 day 3 




Table 4. 9: Analyst 2 day 1, Analyst 2 day 2 and Analyst 2 day 3. 
 




P value 0,0408 
Exact or approximate P value? Approximate 
P value summary * 
Are means significantly different? (P < 0.05) Yes 
Number of groups 3 
Friedman statistic 6,4 
Data summary 
 
Number of treatments (columns) 3 
Number of subjects (rows) 20 
 
 




Multiple comparison of Analyst 2 day 1, Analyst 2 day 2 and Analyst 2 day 3 
 
 
Multiple comparison       
Number of families 1      
Number of comparisons 
per family 
3      







Summary Adjusted P 
Value 
  
Analyst 2 day 1 vs. 
Analyst 2 day 2 
6 No ns >0,9999 D- 
E 
 
Analyst 2 day 1 vs. 
Analyst 2 day 3 
6 No ns >0,9999 D- 
F 
 
Analyst 2 day 2 vs. 
Analyst 2 day 3 
0 No ns >0,9999 E- 
F 
 






n1 n2 Z 
Analyst 2 day 1 vs. 
Analyst 2 day 2 
44 38 6 20 20 0,94 
87 
Analyst 2 day 1 vs. 
Analyst 2 day 3 
44 38 6 20 20 0,94 
87 
Analyst 2 day 2 vs. 
Analyst 2 day 3 
38 38 0 20 20 0 
 
Table 4. 10: Analyst 3 day 1, Analyst 3 day 2 and Analyst 3 day 3. 
 




P value >0,9999 
Exact or approximate P value? Approximate 
P value summary Ns 
Are means significantly different? (P < 0.05) No 
Number of groups 3 
Friedman statistic 0 
Data summary 
 
Number of treatments (columns) 3 







Multiple comparison of Analyst 3 day 1, Analyst 3 day 2 and Analyst 3 day 3 
 
 
Multiple comparison       
Number of families 1      
Number of comparisons 
per family 
3      







Summary Adjusted P 
Value 
  
Analyst 3 day 1 vs. Analyst 
3 day 2 
0 No ns >0,9999 G- 
H 
 
Analyst 3 day 1 vs. Analyst 
3 day 3 
0 No ns >0,9999 G-I  
Analyst 3 day 2 vs. Analyst 
3 day 3 
0 No ns >0,9999 H-I  






n1 n2 Z 
Analyst 3 day 1 vs. Analyst 
3 day 2 
40 40 0 20 20 0 
Analyst 3 day 1 vs. Analyst 
3 day 3 
40 40 0 20 20 0 
Analyst 3 day 2 vs. Analyst 
3 day 3 
40 40 0 20 20 0 
 
 
Table 4. 11: Analyst 1 day 1, Analyst 2 day 1 and Analyst 3 day 1. 
 




P value 0,0067 
Exact or approximate P value? Approximate 
P value summary ** 
Are means significantly different? (P < 0.05) Yes 
Number of groups 3 
Friedman statistic 10 
Data summary 
 
Number of treatments (columns) 3 




Multiple comparison of Analyst 1 day 1, Analyst 2 day 1 and Analyst 3 day 1 
 
Multiple comparison       
Number of families 1      
Number of comparisons 
per family 
3      







Summary Adjusted P 
Value 
  
Analyst 1 day 1 vs. 
Analyst 2 day 1 
-7,5 No ns 0,707 A- 
D 
 
Analyst 1 day 1 vs. 
Analyst 3 day 1 
0 No ns >0,9999 A- 
G 
 
Analyst 2 day 1 vs. 
Analyst 3 day 1 
7,5 No ns 0,707 D- 
G 
 






n1 n2 Z 
Analyst 1 day 1 vs. 
Analyst 2 day 1 
37,5 45 -7,5 20 20 1,1 
86 
Analyst 1 day 1 vs. 
Analyst 3 day 1 
37,5 37,5 0 20 20 0 
Analyst 2 day 1 vs. 
Analyst 3 day 1 




Table 4. 12: Analyst 1 day 2, Analyst 2 day 2 and Analyst 3 day 2. 




P value 0,6065 
Exact or approximate P value? Approximate 
P value summary Ns 
Are means significantly different? (P < 0.05) No 
Number of groups 3 
Friedman statistic 1 
Data summary 
 
Number of treatments (columns) 3 




Multiple comparison of Analyst 1 day 2, Analyst 2 day 2 and Analyst 3 day 2 
 
Multiple comparison       
 
Number of families 
 
1 
     
Number of comparisons 
per family 
3      







Summary Adjusted P 
Value 
  
Analyst 1 day 2 vs. 
Analyst 2 day 2 
-1,5 No ns >0,9999 B- 
E 
 
Analyst 1 day 2 vs. 
Analyst 3 day 2 
0 No ns >0,9999 B- 
H 
 
Analyst 2 day 2 vs. 
Analyst 3 day 2 
1,5 No ns >0,9999 E- 
H 
 






n1 n2 Z 
Analyst 1 day 2 vs. 
Analyst 2 day 2 
39,5 41 -1,5 20 20 0,23 
72 
Analyst 1 day 2 vs. 
Analyst 3 day 2 
39,5 39,5 0 20 20 0 
Analyst 2 day 2 vs. 
Analyst 3 day 2 




Table 4. 13: Analyst 1 day 3, Analyst 2 day 3 and Analyst 3 day 3. 




P value 0,4724 
Exact or approximate P value? Approximate 
P value summary Ns 
Are means significantly different? (P < 0.05) No 
Number of groups 3 
Friedman statistic 1,5 
Data summary 
 
Number of treatments (columns) 3 




Multiple comparison of Analyst 1 day 3, Analyst 2 day 3 and Analyst 3 day 3 
 
Multiple comparison       
Number of families 1      
Number of comparisons 
per family 
3      







Summary Adjusted P 
Value 
  
Analyst 1 day 3 vs. 
Analyst 2 day 3 
1,5 No ns >0,9999 C- 
F 
 
Analyst 1 day 3 vs. 
Analyst 3 day 3 
3 No ns >0,9999 C- 
I 
 
Analyst 2 day 3 vs. 
Analyst 3 day 3 
1,5 No ns >0,9999 F-I  






n1 n2 Z 
Analyst 1 day 3 vs. 
Analyst 2 day 3 
41,5 40 1,5 20 20 0,23 
72 
Analyst 1 day 3 vs. 
Analyst 3 day 3 
41,5 38,5 3 20 20 0,47 
43 
Analyst 2 day 3 vs. 
Analyst 3 day 3 
40 38,5 1,5 20 20 0,23 
72 
 
4.6 Correlation between FPA and standard tests such as RBT and CFT 
 
Table 4. 14: Correlation of Positive samples. 
 
Correlations 
  RBT CFT FPA 








N 419 419 419 








N 419 419 419 









N 419 419 419 




Table 4. 15: Correlation of Negative samples. 
 
 Correlations    
 RBT SAT  FPA 
RBT Pearson Correlation .a a     .a 
  
Sig. (2-tailed) 
   
 
N 446 446 446 
SAT Pearson Correlation .a .a .a 
  
Sig. (2-tailed) 
   
 
N 446 446 446 
FPA Pearson Correlation .a .a 1 
  
Sig. (2-tailed) 
   
 
N 446 446 446 




4.7 Determination of RBT, and CFT limit of the lowest detection 
The lowest detection of RBT was at row 12. The plates were read under the RBT reading 
UV light box. Agglutination was visible, meaning a positive reaction was visible until row 
12. The lowest detection of CFT was at row 11 where there was sedimentation of SRBC 
observed was positive prior to complete haemolysis.   
 
Table 4. 16: Lowest detection of RBT, CFT and FPA. 
Sample id (17) Day 1 Day 2 Day 3 
RBT 2/512 1/256 1/4096 
CFT 2/2048 1/512 4/4096 
FPA - - - 
 
 
The lowest concentration of FPA in serum was not performed due to the computers at 
Onderstepoort being replaced with the new ones, which caused a loss of FPA software. The 






4.8 RBT, CFT and FPA turnaround time 
 
RBT: The turnaround time for RBT is as follows: 30 min for samples and reagents to reach 
room temperature, 3 min plate marking, 30 min for 100 sample and antigen dispensing, 4 
min on shaker and 5 min sample interpretation. The total amount of time it would take to 
perform RBT would be 72 minutes maximum to test 100 samples. The overall assay would 
depend on how many samples the laboratory tested including signing of the results and 
sending them back to the State veterinarian. 
CFT: Based on turnaround time CFT is time-consuming as you have to do the blood 
washing, preparing of the reagents, incubating the inactivated sera which is 30 minutes at 
58 ºC ± 2 ºC in a hot-air oven. The test plates and anti-complementary plates will be 
incubated for another 30 minutes at 37 ºC. After 30 minutes, 50µl haemolytic system was 
added into the test plate and anti-complementary plates then incubated again for 30 
minutes in the shaker. The breakdown for CFT is as follows: 90 min sample preparation, 
60 min blood wash and antigen and buffer preparation, 30 min incubation, 15 min titration 
and antigen dispensing, 30 min incubation, 10 min HS dispensing, 30 min incubation, 3 min 
centrifuge and 15 min interpretation of the results. The total amount of time it would take to 
perform CFT would be 14 hours. The process of performing the test normally takes 2 days 
to complete. Recording of the results and capturing them in the system will take another 
day. The overall assay would take about a week including signing of the results and 
sending them back to the State veterinarian. 
FPA: The breakdown for the FPA was as follows: 10 min sample preparation, 5 min buffer 
preparation, 5 min sample and buffer dispensing, 6 min shaking and incubation, 4 min blank 
reader, 2 min tracer and 3 min sample interpretation. 
The total amount of time it would take to perform the FPA test would be 35 minutes’ 
maximum. The kit’s manufacturer has informed the researcher and the supervisors about 
the latest automated version of the PHERAstar reader (BMGPHERAstar) which seems to 
be more rapid. You only dispense 25 µl of sample into the 96 well plate, load the plate into 
the machine. The FPA reader adds the sample diluent and tracer. Results are calculated 
by Gen 5 software. With this system, it would take approximately 10-15 minutes to perform 




CHAPTER 5: DISCUSSION 
 
In the present study, six samples that tested positive with RBT and CFT tested negative 
with FPA. This may indicate false positive with RBT and CFT as false positive can occur 
related to the condition of the serum samples or vaccination status of animals.  Fifteen 
samples that tested negative with all three tests. Currently, the Rose Bengal test is used 
as a rapid screening test.  Only samples testing positive on RBT are then processed further 
to be confirmed with CFT. A study by Kangumba (2015) reported that the RBT could show 
false- positive results because of S19 vaccination or non-specific serological reactions 
(Kangumba, 2015). A study by Geresu and Kassa (2016) reported that RBT has some 
disadvantages of low sensitivity particularly in chronic cases, relatively low specificity in 
endemic areas and prozones that cause strongly positive sera to test negative. Therefore, 
positive samples are missed from the onset when relying on RBT as a screening test that 
determines the confirmation with CFT. Furthermore, eight samples that tested positive 
with RBT and CFT reacted as suspect with FPA. 
Two hundred and sixty-two positive samples tested positive in four serological assays 
(RBT, SAT, CFT, FPA). Only one sample from known negative herd tested positive for all 
three serological tests. Strongly positive sera can lead to false negative on RBT. That could 
explain why some samples that tested negative on RBT tested positive with FPA. 
The optimum cut-off value for FPA offering the highest ‘‘performance index’’ (sum of DSn 
and DSp) was determined by ROC analysis in two ways, one using as positive reference 
sera originating from positive animals as confirmed by CFT (n=347) and sera from 
negative herds testing negative on RBT and SAT (n=446). Using the two different panels of 
positive and negative reference sera, the accuracies of all tests were assessed from AUC 
values calculated by ROC analysis, as well as their performance from determination of 
Youden’s J value, which is the indicator of the test’s DSn and DSp sum, by cross-tabulation 
(Armitage and Berry, 1994). The FPA cut-off value used as positive (originated from  
positive animals confirmed by CFT) was determined at 87.25 mP, this value is almost 
similar with the one determined by (Nielsen et al., 2005) in an evaluation study for FPA’s 
performance on goat sera. At this cut-off, DSp and DSn were determined at 99.09% - 




 The DSp did not differ significantly from DSp of 98.6, 99.4 and 98.9% found in sheep and 
goats studies (Nielsen et al., 2001and Nielsen et al., 2005), while DSn is higher than 91.5, 
94.9 and 88.7% found in the same studies. 
 
The lowest concentration of FPA in serum was not performed due to the computers at 
Onderstepoort being replaced with the new ones that caused the loss of FPA software and 
the dilution of FPA was not performed. All data were entered manually into a Microsoft Excel 
spread sheet for data cleaning analysis and it was carried out using a Graph pad prism and 
Statistical package for the social science that reduced the number of positive sera (n=493 




CHAPTER 6: CONCLUSION AND RECOMMENDATIONS 
 
The prevention and control of brucellosis in domestic livestock is by vaccination. The use of 
B. abortus strain S19 that remain the reference vaccine in cattle, and it has extremely 
reduced its incidence in many endemic areas. Vaccination of livestock increases the value, 
productivity and induces good immunity of the animal. It does not only improve the health 
status of the animals but also is an important step to reduce the risk of severe illness and 
the transmission to human population (Bano and Lone, 2015) 
 
According to our criteria for positive samples, there should be at least one culture positive 
animal from the herd, but it was difficult to get samples from known positive herds confirmed 
by Brucella bacterial isolation. It appeared that the job of animal health technicians most of 
the time ends after branding the positive serological reactors. Consultations with Dr. 
Grobler, the State veterinarian in Pretoria regarding the negative herds that did not show 
reaction for the past 1 year (as per our criteria) were unfruitful because it was difficult to 
trace back the animals as some of the farmers had sold those animals and introduced new 
animals in the herd. 
Due to these challenges, it was decided to evaluate the status of the herds according to 
the serological profile. Herds that had many serological reactors with several high titres 
were classified as serologically positive herds. Negative herds were classified based on 
negative RBT and SAT results. 
The turnaround time of FPA is unrivalled for speed, with test completion in as little as 35 
minutes, requiring no washing steps or long incubation. As a one-step solution, it can be 
performed in a laboratory or field setting with few reagents required. FPA has a leading 
performance yielding quantitative results. The sensitivity of FPA was greater and specificity 
was lower than those of the tests currently in use. 
Future perspectives 
 
• Collaboration with general bacteriology will focus on tracing animals that have been 
identified as positive after isolation of Brucella spp. 
• At least one publication in an accredited journal is expected from this study. 




PHERAstar reader (BMGPHERAstar) which seems to be more rapid as it is fully 
automated as mentioned in 4.8 above, turnaround time of FPA.  
• Fluorescence Polarization Assay should FPA be given a chance as a diagnostic 
test in South Africa, it will be an asset to brucellosis control programs. The FPA is 
relatively preferable compared to the other test that were used and has other 
advantages, including its accuracy, less time to perform the assay, electronic data 
entered into an excel worksheet meaning quick results will be obtained, and a 
record of results can be printed and sent directly to the state veterinary (Gall et al., 
2001). 
• Validation is an ongoing activity that is crucial to all accredited laboratories, and after 
the completion of this study, laboratories will continue with validation especially if 
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